Maarten van Geffen's career in the industry spans nearly 25 years, with substantial experience in pharmaceutical product development and regulatory affairs. He recently stopped his consultancy Amplipharm consulting BVBA to join Janssen Vaccines as Senior Scientist drug product development. His last assigned on behalf of Amplipharm Consulting BVBA was to support Janssen Vaccines NV and to develop an orphan drug to fasttrack an ALS product development on behalf of 3D-PharmExchange and Treeway NV. Before the last assignment Maarten supported Amakem NV and Ophtakem NV as Vice President CMC, Operations and Quality. Maarten was previously Director of Product Development at Shire-Movetis NV, where he was responsible for the pharmaceutical development of the GI early and late phase products and was the CMC lead for due diligence of early phase and late phase small and large molecule products. While at the Company, Maarten also played a pivotal role in the strategic development of commercial and pipeline products as well as carrying out quality control on dossiers and interacting with regulatory authorities. Prior to working at Shire-Movetis NV, Mr. van Geffen held several positions as Director of CMC Regulatory Affairs at Barrier Therapeutic NV, Centocor BV, and Janssen Research Foundation, where he was involved in managing and executing product development and regulatory approval. Before initiating his career in the industry Mr. Van Geffen was assessor of quality part biological pharmaceutical dossiers for the Dutch Health and Environmental agency. Mr. van Geffen received an MSc in Biology from the University of Utrecht, the Netherlands.